Profit Matters!  Small Stocks. Huge Gains.
  • Home
  • Market News
  • HOT Picks
  • Services
  • SUCCESS Stories
  • Clients
  • Contact
Aethlon Medical, AEMD, Profile, Summary  E-mail
Written by Administrator   

 

Aethlon Medical, AEMD, Profile, Summary



Aethlon Medical (AEMD) is developing innovative medical devices to address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Aethlon’s ADAPT™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as HIV and Hepatitis C.

 

HER2 Protein and Breast Cancer

Breast cancer is the most common form of cancer in women, accounting for 20% of cancer deaths with approximately 180,000 women diagnosed annually in the United States (Merrill, R. M., and A. Sloan. 2011. Risk-adjusted female breast cancer incidence rates in the United States. Cancer Epidemiol.). Over-expression of the human epidermal growth factor receptor 2 (HER2; ErbB2) gene occurs in approximately 25% of breast cancers and has been linked to poor prognosis (Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182). HER2 is a receptor tyrosine kinase, member of the EGF receptor family, which possesses proliferative and anti-apoptotic activities.

 

The standard of treatment for women diagnosed with HER2+ breast cancer includes the humanized monoclonal antibody trastuzumab (marketed as Herceptin®) directed against the extracellular domain of HER2. Trastuzumab binding to HER2 mediates direct growthinhibition of tumor cells and induces antibody-dependent cell cytotoxicity (ADCC), a major anti-cancer mechanism by which natural killer (NK) cells lyse antibody-coated tumor cells (Nahta, R., D. Yu, M. C. Hung, G. N. Hortobagyi, and F. J. Esteva. 2006. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269-280).

 

In patients with metastatic breast cancer undergoing chemotherapy, treatment with trastuzumab augments overall response rates and increases median survival time by 25% (Baselga, J. 2001. Clinical trials of Herceptin® (trastuzumab). Eur J Cancer 37 Suppl 1:18-24). However, response rates to trastuzumab range from 12% to 34% with median duration of 9 months due to development of resistance. Despite co-treatment with other HER2 targeting therapies (e.g. the tyrosine kinase inhibitor lapatinib) and chemotherapy, patients with metastatic breast cancer experience a limited duration of benefit; therefore, novel treatment strategies that act synergistically or overcome drug resistance are urgently needed (Sachdev, J. C., and M. Jahanzeb. 2011. Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer.

 

The Evolution of Therapeutic Filtration to Improve Hepatitis-C Virus (HCV) Treatment Outcomes

 

Therapeutic filtration of HCV from the entire circulatory system with a medical device has been clinically demonstrated to improve treatment outcomes when administered at the outset of standard of care (SOC) drug therapy. This summary overview, which includes an introduction to the Aethlon Hemopurifier®, is for informational purposes only.

 

About HCV Infection

The U.S. National Institutes of Health (NIH) reports an estimated 180 million people worldwide are afflicted with chronic HCV infection. Of people infected, 55 to 85% of will develop chronic infection, and 75% of those will develop chronic liver disease. Standard of care (SOC) drug therapy is represented by a two drug combination of interferon and ribavirin. The primary goal of SOC drug therapy is the achievement of a sustained virologic response (SVR), defined as undetectable viral load six months after completion of SOC drug therapy. According to the NIH, 15-25% of HCV infected patients will recover

completely.

 

SOC Drug Therapy Outcomes

•The largest study of HCV infected individuals pursuing 48-week SOC drug

therapy was a study of 4,469 genotype 1 patients published by McHutchison in The New England Journal of Medicine in August of 2009.

•31% (1,399 of 4,469) of patients screened for participation were excluded from the study.

•54% (1,654 of 3,070) of treated patients completed the SOC treatment regimen.

•39.6% (1,215 of 3,070) of treated patients who completed SOC therapy

achieved a SVR.

•27% (1,215 of 4,469) of the total patients screened for study participation

achieved a SVR.

•No data recorded for patients who may have relapsed after achieving a SVR.

 

The Hemopurifier®

The first medical device to selectively remove HCV and related immunosuppressive proteins from circulation. A Study of the Hemopurifier® + SOC Drug Therapy is Now Underway

 

•Patient enrollment has been initiated at the Medanta Medicity Institute in India - www.medanta.org

•Additional details can be accessed from the Clinical Trials Registry - India (CTRI) link: http://ctri.nic.in/clinicaltrials/index.jsp

•Up to 30 patients / up to 6 treatments in first 3 days of SOC

•Early clinical endpoints include:

•Immediate Virologic Response (IVR)

•Rapid Virologic Response (RVR)

•Early Virologic Response (EVR)

 

The Hemopurifier® Other Selected Quick Facts

 

•70 human treatment experiences administered to date

•An Investigation Device Exemption (IDE) to initiate U.S. studies has been filed with FDA

•Substantial viral load reductions have also been observed in a human HIV study performed in the absence of antiviral drugs

•GMP manufacturing has been established in an FDA approved facility

•The Hemopurifier® has proven broad-spectrum capabilities against viral bioterror and pandemic threats

•The device has been discovered to capture tumor-secreted exosomes known to suppress the immune system of cancer patients

 

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you would like your company featured or want to learn more, please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.com

ALS, Hepatitis C, Traumatic Brain Injury, Blood Sepsis,breast cancer,HIV,HPV,HCV,SOC, dialysis,DOD,UNT,USPTO, NFL,SOCCOR,MILITARY,COMBAT MISSIONS,PTSD, Ebola


 
Premier Biomedical, BIEI, Profile, Summary  E-mail
Written by Administrator   
Sunday, 02 November 2014 00:29

 

Premier Biomedical | BIEI | Profile | Summary


Premier Biomedical (BIEI) is a research-based company that has acquired exclusive licenses for patent-pending medications and medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses: ALS, Traumatic Brain Injury, Multiple Sclerosis, Clinical Depression, Alzheimer’s Disease, Blood Sepsis, and Cancer. The company is in the process of developing targeted medicines and procedures and will prove out their superior efficacy in addressing these diseases and others through laboratory, hospital, and actual patient applications. At the anticipated successful conclusion of the clinical trials, contact will be established with the leading worldwide pharmaceutical firms to establish the right to market and distribute Premier Biomedical’s technology products and procedures.

 

INVESTMENT HIGHLIGHTS

· The Company’s proprietary Sequential Dialysis Technique and patented candidate drug Feldetrex are expected to provide superior efficacy versus existing medications in treating a large number of the most fatal diseases

o Alzheimer’s Disease, Multiple Sclerosis, ALS, Fibromyalgia, Traumatic Brain Injury, Blood Sepsis, and Cancer

 

· The Company has established two outstanding research partnerships with the University of Texas, El Paso (UTEP) and the Department of Defense

o Leverage the substantial infrastructure and resourced capacity of these organizations to perform experimentation and to engage in product development in an inexpensive and efficient manner

o Positive results in animal testing for the Sequential Dialysis Technique treatment of cancer

o Initiation of two clinical trials including a trial for Feldetrex and a trial of the Sequential Dialysis Technique



EXECUTIVE SUMMARY

· Premier Biomedical is a research-based company that intends to discover and develop medical treatments targeting the treatment of:  Alzheimer’s Disease, Multiple Sclerosis, ALS, Fibromyalgia, Traumatic Brain Injury, Blood Sepsis, and Cancer

 

· The Company’s proprietary Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without dangerous side effects

o Superior to current treatments which eliminate the presence of most illnesses but often with catastrophic or even fatal side effects

o Targets cancer, Alzheimer’s disease, Multiple Sclerosis, ALS, blood sepsis, and Traumatic Brain Injury – collectively over $700 billion market opportunity

 

· Developed a proprietary drug candidate Feldetrex as a potential treatment for Multiple Sclerosis, Fibromyalgia, and Traumatic Brain Injury

o Expected to deliver significant relief to patients, while presenting fewer side effects than other alternate medications

o The Company was recently granted two US patents for this drug candidate

o The annual market size of all proposed market segments for Feldetrex is $16 billion

 

· The Company has established two outstanding research partnerships with the University of Texas, El Paso (UTEP) and the Department of Defense

o Leverage the substantial infrastructure and resourced capacity of these organizations to perform experimentation and to engage in product development in an inexpensive and efficient manner

o Positive results in animal testing for the Sequential Dialysis Technique treatment of cancer

o Initiation of two clinical trials including a trial for Feldetrex and a trial of the Sequential Dialysis Technique

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you would like your company featured or want to learn more, please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.com

Alzheimer’s Disease, Multiple Sclerosis, ALS, Fibromyalgia, Traumatic Brain Injury, Blood Sepsis,Cancer,sequential dialysis

techniques,DOD,UNT,UofT,USPTO, NFL,SOCCOR,MILITARY,COMBAT MISSIONS,PTSD.

Last Updated on Sunday, 02 November 2014 01:13
 
Axxess Pharma, AXXE, Profile, Summary  E-mail
Written by Editor   
Wednesday, 22 October 2014 09:18

Axxess Pharma, AXXE, Profile, Summary

Axxess Pharma (AXXE) is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain as wells as nutritional supplements.

 

Axxess Pharma is dedicated to providing a wide range of products to improve the lives of patients and consumers worldwide.

Axxess Pharma intends to market these products with affordable pricing and widespread availability. The products are targeted to improve health-related conditions including several forms of iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections, infant cradle cap, joint pain and much more. Axxess Pharma will continue to tap the well of innovation to develop ever-more effective and affordable treatment options for the patients.

Axxess Pharma Signed an Exclusive World-Wide License to Market and Sell TapouT Brand Vitamins & Minerals Pain Relief and Muscle Recovery Products. http://shop.tapout.com/

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Want to get your company featured? or have questions/comments, please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.com


Last Updated on Sunday, 02 November 2014 00:39
 
Dalton Industries, DALT, Profile, Summary  E-mail
Written by Editor   
Tuesday, 14 October 2014 08:55

Dalton Industries, DALT, Profile, Summary

 

Dalton Industries (DALT) , conducts research and development in the Visual FX, Games and Digital Content Creation industries. Over the years we worked on a variety of feature film, television and game productions creating pipelines, CG art and providing supervision and consultation services in these areas. Dalton aslo makes tools, both hardware and software for users who work in these areas, leveraging their knowledge and experience into commercial products.

Dalton Industries Inc., has been working with various tools and devices related to the Virtual Reality and Augmented Reality industries for the last 2 years.Yet our research efforts go back to the dawn of Virtual Reality in the early 1990s, building our own head mounted displays.

The company is currently working on two software products for commercial release that relate to the Oculus Rift Virtual Reality Head Mounted Display Device and Leap Motion’s Leap Controller for use with content creation packages popular in the Visual FX, Games, 3D Animation and Audio production industries.

Dalton Industries continue to invest in Research and Development with with software products as well, such as the highly acclaimed and heavily used UberCam for LightWave3D. Originally intended exclusively for our own use, UberCam is now one of our most successful tool based products sold through Liberty3d.com. This is a common pattern for us. We build these tools to help us in our work on productions for clients as well as our own projects eventually turning them into commercial products retailed to the industry.

From stereoscopic virtual cameras to character animation and modeling tools in Computer Graphics, our products are being used by artists worldwide. Chances are that if you are a fan of sci-fi and have been watching TV and movies over the last decade you have seen shots that were created using our tools and methodologies.

With the increasing dependence of productions on Visual Effects and Digital Content Creation Tools, Dalton is committed to Research and Development of next generation technology and products in these areas has never been greater.

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Want to get your company featured? or have questions/comments, please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.com


Last Updated on Thursday, 16 October 2014 10:54
 
Integrated Environmental Tech, IEVM, Profile, Summary  E-mail
Written by Administrator   
Monday, 06 October 2014 16:33

Integrated Environmental Tech, IEVM, Profile, Summary



Integrated Environmental Technologies (IEVM), markets and sells anolyte disinfecting solution under the Excelyte™ brand name and sells a cleaning solution under the Catholyte Zero™ brand name. Both solutions are produced by the Company’s proprietary EcaFlo™ equipment which utilizes an electrolytic process known as electrochemical activation to reliably produce environmentally responsible solutions for cleaning, sanitizing and disinfecting. Excelyte™ solutions are EPA-registered hard surface disinfectants and sanitizers approved for hospital-level use and are also approved for use as a biocide in oil and gas drilling. The products can be used safely anywhere there is a need to control pathogens, bacteria, viruses, and germs. Catholyte Zero™ solutions are an environmentally friendly cleanser and degreaser for janitorial, sanitation and food processing uses. The Company is currently focused on selling its Excelyte™ solutions to oil and gas production companies, healthcare facilities and agriculture and dairy farmers.

Oil & Gas Industry

Excelyte™ is being adopted by natural gas producers in the western U.S., especially in Utah and New Mexico.

Excelyte™ is considered an industry leader in being able to provide an environmentally conscious solution for disinfecting and sanitizing. It is EPA registered as an antimicrobial. For more than 20 years, Excelyte™ has been used for the enhancement of oil and gas production. It is frac fluid compatible and pH neutral. It is certified by the NSF, USDA, and EPA. It is the only EPA-registered disinfectant that has been proven completely effective against all bacteria and virus tested. We provide customers with chemical-free science-based disinfecting, sanitizing and cleaning solutions produced by ECA technology to promote environmental, worker and consumer health safety wherever pathogens must be controlled



Excelyte’s™ unique ability to disrupt viruses and bacteria cell structure while being able to fully degrade leaving no ecological footprint behind, makes it both strong but safe in many applications. The ability to disrupt the cell structure prevents organisms from mutating and becoming resistant, reduces the possibility of superbugs. It does not become resistant to microbes, as do most chemicals. It kills oil field bacteria with no harmful by-products. Excelyte™ carries a NSF-61 Water Treatment equipment certification and is considered non-hazardous by the US Department of Transportation. Protective equipment and site safety measures are not required for Excelyte™ applications. Once Excelyte™ has fully degraded, it leaves no ecological damage to well sites.

For every one million gallons of water used, we only need to add about 5,000 gallons of Excelyte™ to treat at 2.5ppm. It costs millions of dollars per frack per well but the cost of adding Excelyte™ is a fraction of a percentage of that overall cost.

Excelyte™ has been registered by the EPA for use in the following applications:

  • Fractured & Produced Water

  • Sour Wells

  • Water Flood Injection Waters

  • Oil and Gas Transmission Lines

  • Heater Treaters

  • Hydrocarbon Storage Facilities

  • Gas Storage Wells

Zero Environmental Impact

Kills 99.9999% of microbes, 100% eco-friendly.

EcoTreatments™ produces powerful, eco-friendly disinfecting and sanitizing solutions named Excelyte™ and Catholyte Zero™ using our proprietary EcaFlo™ technologies. Excelyte™ is a powerful antimicrobial solution that is both biodegradable and non-accumulative. The key active ingredient, hypochlorous acid, is derived from naturally occurring salt minerals and water. When exposed to environmental conditions, Excelyte™ quickly degrades into salt and water leaving no ecological footprint.

A BETTER SOLUTION

Ecotreatments™ solutions are an environmentally conscious approach to meet today’s growing demands for disinfecting, sanitizing, and cleaning products that are non-toxic yet eliminate bacteria and viruses where you touch, breath, work and live.

Producing Excelyte™ involves using a simple solution of salt and water to create an environmentally responsible solution with powerful disinfecting characteristics.

Excelyte™ is a powerful antimicrobial solution that is both biodegradable and non-accumulative. The key active ingredient, 0.46% hypochlorous acid, is derived from naturally occurring salt minerals and water.

Excelyte,™ produced by our EcaFlo™ electrolytic cell, is capable of meeting industrial performance standards in quality, reliability, and production capabilities.

NO HARMFUL IMPACT

When exposed to environmental conditions, Excelyte™ quickly degrades into salt and water leaving no ecological footprint.

Much like the human body immune system, Excelyte™ is an antimicrobial solution formed from naturally occurring elements. Excelyte™ attacks an array of microbial organisms including bacteria and viruses.

  • Excelyte™ is non-flammable and contains no alcohol.

  • It can be transported as a non-chemical with no strict HAZMAT requirements

  • Excelyte™ is made up of 99.5% water.

  • Excelyte™ kills viruses and bacteria offering a better alternative to the harmful chemicals in use today for disinfecting and sanitizing.

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Want to get your company featured? or have questions/comments, please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.com

 

TAGS: Fracking, Fracking Treatment, Fracking Water, Fracking Dangers, Fracking Impact. Fracking Gas, Fraking Industry, Fracking Chemicals, Fracking Industry, Fracking Boom, Fracking in USA, Fracking for Gas, what is Fracking.

 
KiOR, KIOR, Profile, Summary  E-mail
Written by Administrator   
Sunday, 17 August 2014 02:36

 

KiOR | KIOR | Profile | Summary



KiOR is a next-generation renewable fuels company that has developed a proprietary technology platform to convert biomass into renewable crude oil that is processed into gasoline, diesel and fuel oil blendstocks. The company built the first commercial scale cellulosic fuel facility in Columbus, MS, which started production in 2012. KiOR strives to help ease dependence on foreign oil, reduce lifecycle greenhouse gas emissions and create high-quality jobs and economic benefit across rural communities.



Key differentiating factors about KiOR include:

  • Breakthrough technology that leverages proven process

  • Ability to use of abundant non-food feedstocks

  • Access to a vast global market and large base of customers

  • Experienced management team that can deliver accelerated growth.

 

Technology

KiOR has developed a proprietary technology platform to convert sustainable, low-cost, non-food biomass into a hydrocarbon-based renewable crude oil. Using standard refining equipment, the company processes its renewable crude into gasoline and diesel blendstocks that can utilize the existing transportation fuel infrastructure for use in vehicles on the road today.

In essence, KiOR’s technology simply reduces the time it takes to produce oil from millions of years to a matter of seconds. The company’s technology platform combines its proprietary catalyst systems with a process based on existing Fluid Catalytic Cracking (FCC) technology, a standard process used for over 60 years in oil refining. The efficiency of KiOR’s process, called Biomass Fluid Catalytic Cracking (BFCC), and the proven nature of catalytic cracking technologies allow for significant cost advantages, including lower capital and operating costs, versus traditional biofuels producers.

KiOR processes its renewable crude oil in a conventional hydrotreater, which is a standard process unit used in oil refineries, into gasoline and diesel blendstocks that can be combined with existing fossil-based fuels and used in vehicles on the road today.


Products

 

KiOR produces renewable gasoline and diesel blendstocks that are comparable to their fossil-fuel based counterparts and can easily be dropped-in to the existing fuel supply, offering a more environmentally friendly fuel option to consumers at the pump. According to a full lifecycle emissions analysis of KiOR data, based on the Argonne National Laboratory's Greenhouse Gases, Regulated Emissions and Energy Use in Transportation, or GREET model, using KiOR'sdata, KiOR’s gasoline and diesel blendstocks are projected to reduce direct lifecycle greenhouse gas emissions by more than 80% compared to fossil-based gasoline and diesel.

Given the infrastructure compatibility of its renewable fuels, KiOR expects to access the $2 trillion global transportation fuels market while also benefiting from government programs, such as the US Renewable Fuel Standard.

KiOR’s renewable blendstocks can be combined with conventional gasoline and diesel fuels by refiners and oil companies and sold to distributors of finished products, or end users of fuel products. To date, KiOR has signed fuel offtake agreements with Hunt Refining, Catchlight Energy, and FedEx Corporate Services, thus demonstrating its ability to fulfill the needs of a variety of customers.


Greenhouse Gas Reductions

 

While KiOR’s blendstocks are comparable to their fossil fuel-based counterparts, because they are made from renewable biomass, they can contribute to significant reductions in carbon emissions. In fact, on a full lifecycle basis, KiOR’s gasoline and diesel blendstocks are projected to reduce greenhouse gas emissions by over 80% compared to the fossil-based fuels they displace, according to an analysis of KiOR data by TIAX LLC.

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you want to get your company profiled or have questions/comments, please don't hesitate to contact the Editor [@] OxBridgeResearch.com


Last Updated on Friday, 19 September 2014 11:07
 
ZaZa Energy , ZAZA, Profile, Summary  E-mail
Written by Administrator   
Monday, 16 June 2014 12:36

 

ZaZa Energy , ZAZA, Profile, Summary

 

 

ZaZa Energy Overview

 

CONSOLIDATING A DOMINANT POSITION IN THE EAGLEBINE

 

 High concentration of liquid‐rich assets in the Eaglebine and Eagle Ford trends

 ~110,000 acre presence within the Eaglebine and Lower Cretaceous window

 7,600 acres surrounded by Devon’s recently acquired $6 billion GeoSouthern Eagle Ford assets

 Completed amendment to Eaglebine/Eagle Ford East joint venture agreement with large independent operator

 Accelerated timing

 Contiguous JV acreage footprint

 Immediate liquidity (~$17.8MM net cash) and production (~$17MM in PDP value)

 6 well carry program

 Proven management team

 Significant experience with majors and large independents

 Collectively participated in the drilling and completion of over 5,500 wells

 

UNCONVENTIONAL ASSETS – POST CONVENTIONAL THINKING

 

 Technical evaluation of the juncture between the organic‐ and carbonaterich Eagle Ford group and the silica‐rich Woodbine plays provided an operational thesis to make the Eaglebine an area of primary focus

 Analogous to mature Eagle Ford area

 Large potential resource play with stacked pay

 Oil/liquids rich in multiple zones

 Multiple zones act as an acreage multiplier

 Significant successful offset activity

 

MILESTONES - POSITIONED FOR RAPID VALUE CREATION-

 

˃ Secured a first mover advantage in the Eaglebine/Eagle Ford East play

˃ Consummated joint venture agreement with a large independent operator to develop Eaglebine/Eagle Ford East acreage

˃ Accelerated original joint venture agreement through an amendment to acquire additional production and further develop our acreage block

˃ Entered joint venture agreement with Sabine Oil & Gas LLC, a First Reserve portfolio company, to develop Sweet Home Eagle Ford acreage

˃ Strategically completed sale of non‐core Moulton Eagle Ford assets for approximately $38 million

˃ Reduced senior secured notes to $26.8 million from $100 million

˃ Drilled and completed 4 proof‐of‐concept wells during 2013

 

EAGLE FORD SHALE PROPERTIES

 

JOIN VENTURE

 

Sabine Oil & Gas LLC (“Sabine”) and ZaZa entered into a 75/25 joint venture for the development of ZaZa’s Sweet Home prospect in the Eagle Ford trend located in the liquids window of De Witt and Lavaca Counties, Texas

 Sabine carries ZaZa for two commitment wells and up to $750,000 of construction costs related to gathering and infrastructure in exchange for a 75% interest in 7,600 net acres and the Boening well. Sabine also carries up to

$300,000 of ZaZa’s expenses related to the extension and renewal of certain leases

>> If Sabine completes the first commitment well by February 15, 2014, ZaZa will transfer to Sabine a 75% interest in approximately 3,200 net acres and the Boening well

>> If Sabine completes the second commitment well by April 15, 2014, ZaZa will transfer to Sabine a 75% interest in the remaining net acres (4,400)

• Assuming the initial two commitment wells are successful in achieving production, participating interests in any additional wells drilled or lease

acreage acquired in the Sweet Home prospect will be shared 75% by Sabine and 25% by ZaZa under an Area of Mutual Interest (“AMI”) that will expire

on September 15, 2015

 

SWEET HOMEPROSPECT

 

 +200’ thick Eagle Ford pay section with >8% porosity in

thickest portion of organic shale

 Adjacent to and surrounded by Devon’s recently acquired $6 billion GeoSouthern Eagle Ford assets

>> Visible oil growth in low‐risk, repeatable play

 ZaZa’s Boening well began with an initial production rate of 669 Boe/d

 

PROVEN BUSINESS MODEL

 

 

Initial Appraisal

 

• Regional geologic evaluation

• Depositional model, subsurface analysis, 3D seismic

• Hydrocarbon system, maturity, geochemistry

• Begin building subsurface model

• In‐depth data analysis

• Analyze all area logs and rasters

• Analyze all nearby core data if available

• Maturity/TOC/XRD, mineral composition, fracability

• Detailed log correlations and custom petrophysics

 

Proof of Concept

 

• Drill pilot well, take full suite of logs and core

• Mud logging, ISO‐analysis, in‐situ fluid composition

• Open‐hole logging (rock properties, matrix mineralogy, clay

type, hydrocarbon saturation, stress analysis, rock mechanics)

• Core analysis

• Maturity/TOC/XRD, mineral composition, fracability

• Core calibrated to petrophysics

• Integration

• Detailed pilot to lateral rock properties calibration

• Custom frac design and execution

• Microseismic monitoring and tracer analysis

 

Capital Markets Access

 

• Strengthening balance sheet

• Optimizing capital structure for growth

• Transact to accelerate cash flow

 

 

Proven Management Team

 

Todd Brooks (Founder, Executive Director, President &

CEO)

 Founded ZaZa Energy, LLC in 2009. Led company into multiple scaled drilling and development JVs in the Eagle Ford and Eaglebine. Took ZaZa public via reverse merger in early 2012

 Principal of Neuhaus Brooks Investments of Texas, LLC, a company making strategic energy investments across multiple geographic regions

 Experienced land man, E&P investor and entrepreneur

 B.A. in Economics from Vanderbilt University; J.D. from South Texas College of Law

 

Ian Fay (CFO)

 

 Founding Partner at Odin Advisors LLC

 Served as Head of the Energy & Natural Resources Group | Americas at BNP Paribas

 Worked as Managing Director for RBC Capital Markets and Director of M&A for UBS Investment Bank

 B.A. in English from the University of North Carolina at Chapel Hill and Morehead‐Cain scholar

 

Kevin Schepel (EVP Exploration and Production)

 

 Executive Vice President of Exploration and Production since June 2010

 Served as Vice President of Worldwide Exploitation for Pioneer Natural Resources, Chief Petrophysicist for BHP Petroleum and 15 years as an advanced Geoscientist at Exxon

 B.S. from Michigan State University; Licensed by the Texas Board of Professional Geoscientists

 

Thomas Bowman (EVP Evaluation, Geology and Geophysics)

 

 Served in various roles such as Evaluation Manager and Exploration Advisor at Aspect Abundant Shale, Bass Enterprises, Fina Oil and Chemical and Tenneco Oil Co.

 Industry‐recognized specialist in identification of resource plays and the utilization of geophysical advancements; involved in the completion of over 1,000 horizontal resource wells across a majority of US shale plays

 B.S. from Montana College of Mineral Science and Technology; Licensed by the Texas Board of Professional Geoscientists

 

The Advantage

 Light Louisiana Sweet crude pricing offers premium relative to

WTI (~$4.50 per Bbl)

 Gas prices benefit from favorable BTU/GPM content and proximity to Houston‐area markets

 Quality infrastructure in place with available takeaway capacity

 

Approach

 

• Identify trends early / first mover

• Low entry cost

• Large contiguous acreage blocks

• Concentrated area focus

• High‐value partnerships

• Oil‐weighted properties

• Latest technology

 

Results

2014 Catalysts

• Viable exploration wells

• Eaglebine development moving forward

• Secure “regularway” financings

 

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you want to get your company profiled or have questions/comments, please don't hesitate to contact the Editor [@] OxBridgeResearch.com

Last Updated on Thursday, 19 June 2014 12:52
 
More Articles...
  • The Alkaline Water Company, WTER, Profile
  • Hyperdynamics, HDY, Profile, Summary
  • Hemispherx Biopharma, HEB, Profile, Summary
  • Bacterin International, BONE, Profile, Summary
«StartPrev12345678910NextEnd»

Page 4 of 72
Joomla SEO powered by JoomSEF
Tweet
 

Today's Top Pick

Get it Now!

 

 

BNVI +43%
RDDY +50%
PTEK +64%
WEST +47%
BPAX +107%
ZOOM +24%
HYSR +69%
Small Stocks. Huge Gains.

 

 

Top 10 Picks
  • ERTS + 9.12%
  • CLWR + 147,56%
  • GSOL + 82.71%
  • DRYS + 57.21%
  • RMG + 28.98%
  • FCX + 142.87%
  • BX + 133.33%
  • RIM + 66.12%
  • CREE + 180.35%
  • MMR + 194.08%
  • Details
Latest Reports

 

  • StationDigital, SDIG, Research Report new

  • Premier Biomedical, BIEI, Research Report new

  • Teryl Resources, TRC.V, TRYLF, Research Report new

  • GenVec, GNVC, Profile
  • Teryl Resources, TRC.V/TRYLF, Profile

  • Anavex, AVXL, Profile
  • Green Innovations,GNIN, Profile

  • LiveWire Energy, LVVV, Profile

  • Stevia (STEV) Research Report new

  • STEV – Stevia Profile

  • Epic (EPOR) Market Intelligence Report new

  • Epic (EPOR) Market Summary new

  • Emgold (EMR.V) Research Report new

  • Emgold (EMR.V, EMGCF) Profile new

  • DTOR.OB, Del Toro, Profile
  • SIGNATURE DEVICES SDVI.PK
  • ZenZuu.com   TCLN.OB
  • HEARTLAND  HTOG.PK
  • ALUMIFUEL POWER  AFPW.OB
  • AFPW.OB  New Update
  • New Energy  NENE.OB
  • Tale of Two Energy Stocks
  • TBIO TRANSGENOMIC
  • GETG, GREEN EARTH TECH
  • UBRG, Universal Bioenergy Profile
  • UBRG Research Report new

 

Disclosure/Disclaimer Terms and Conditions.
© Copyright 2007 OxbridgeResearch.com, All Rights Reserved. Trademarks/logos are of their respective owners.